Adverse Effects

Biomarkers

Brain Cancer

HER2-Positive Breast Cancer

Triple-Negative Breast Cancer

Breast Cancer

Colorectal Cancer

Esophageal Cancer

Gastric Cancer

Liver Cancer

Pancreatic Cancer

Gastrointestinal Cancer

Bladder Cancer

Kidney Cancer

Prostate Cancer

Genitourinary Cancers

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

Gynecologic Cancers

Head & Neck Cancer

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Hematologic Oncology

Hormone-related Cancers

Immunotherapy

Vaccines

Infection

Leukemia

Non-Small Cell Lung Cancer (NSCLC)

Small Cell Lung Cancer (SCLC)

Lung Cancer

Lymphoma

Melanoma

Mesothelioma

Neuroendocrine Tumors

Oncology

Pediatric Cancers

Radiation Oncology

Sarcoma

Screening

Skin Cancer & Melanoma

Surgery

Thyroid Cancer

News

Clinical Topics

Global Bulletin

All News

Approval Alert

Media

2 Minute Drill

Around the Practice

Between the Lines

Breaking Barriers

Face Off

From All Angles

Morning Rounds

OncView

Podcasts

Readout 360

Training Academy

Treatment Algorithms with the Oncology Brothers

Conferences

Publications

All Journals

Editorial Board

For Authors

Events

Frontline Forum

Satellite Sessions

CME/CE

Resources

Contemporary Concepts

Awareness Month

Interactive Tools

Nurse Practitioners/Physician's Assistants

Partners

Career Center

Subscribe

Home to the journal Oncology, Cancer Network provides research and opinion on the screening, early detection, diagnosis, treatment, and prevention of cancers.

About

Advertise

CureToday.com

OncLive.com

OncNursingNews.com

TargetedOnc.com

Editorial

Contact

Terms and Conditions

Privacy

Do Not Sell My Personal Information

Cancer Network

Facebook

LinkedIn

Spotlight

Around the Practice 

Journal

Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice

Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer

Clinical

Acute Myeloid Leukemia

Genitourinary Cancer

Gynecologic Cancer

Hematology

Skin Cancer

1rem

View

CIRCULATE-Japan GALAXY: ctDNA-Based MRD Detection in Colorectal Cancer and Implications for Survival, Treatment, and Risk Stratification

GALAXY Study: ctDNA-Based MRD Monitoring in Resected CRC

Videos

Mike J. Pishvaian, MD, PhD; Stacey Cohen, MD; and Mark Lewis, MD, FASCO, discuss how recent advancements in circulating tumor DNA (ctDNA) and minimal residual disease (MRD) testing are revolutionizing colorectal cancer management across the care continuum, from early detection to treatment selection and monitoring, with key insights from major clinical trials like DYNAMIC and GALAXY informing more personalized and effective treatment strategies.

Panelists discuss how colorectal cancer rates are increasing, particularly among younger adults, while highlighting the potential of circulating tumor DNA (ctDNA) technology to improve early detection and treatment monitoring.

Colorectal Cancer: Rising Prevalence and the Promise of ctDNA

Panelists discuss how circulating tumor DNA (ctDNA) is revolutionizing colorectal cancer (CRC) management by enabling more personalized and precise approaches to diagnosis, treatment selection, and monitoring of disease progression.

ctDNA in CRC Management: Evolving Approaches for Personalized Care

Panelists discuss how minimal residual disease (MRD) detection in colorectal cancer (CRC) is improving postsurgical treatment decision-making and enabling more effective monitoring of patient outcomes.

MRD Detection in CRC: Guiding Postsurgical Treatment Decisions and Monitoring

Panelists discuss how minimal residual disease (MRD) testing in colorectal cancer (CRC) is facilitating the development of chemo-sparing strategies while maintaining effective control of residual disease.

MRD Testing in CRC: Optimizing Chemo-Sparing Strategies and Residual Disease Control

Panelists discuss how the DYNAMIC trial data demonstrate the potential of circulating tumor DNA (ctDNA)–guided therapy to inform and optimize adjuvant chemotherapy decisions in patients with stage II colon cancer.

DYNAMIC: ctDNA-Guided Therapy on Adjuvant Chemotherapy Decisions in Stage II Colon Cancer

Panelists discuss how insights from the INTERCEPT, BESPOKE, COSMOS-CRC-01, and GALAXY studies are advancing our understanding of circulating tumor DNA’s (ctDNA) utility in colorectal cancer management, from early detection to treatment monitoring.

ctDNA Insights From INTERCEPT, BESPOKE, COSMOS-CRC-01, and GALAXY Studies

Panelists discuss how the GALAXY study data demonstrate the effectiveness of circulating tumor DNA (ctDNA)–based minimal residual disease (MRD) monitoring in patients with resected colorectal cancer (CRC), potentially improving postsurgical care and outcomes.

Panelists discuss how results from the GALAXY study reveal that circulating tumor DNA 
(ctDNA) status is a powerful predictor of outcomes and treatment benefit in patients with colorectal cancer (CRC), potentially revolutionizing personalized treatment approaches.


GALAXY Study Results: ctDNA Status Predicts Outcomes and Treatment Benefit in CRC

Between The Lines

 is an engaging 30- to 45-minute open discussion showcasing insightful and impactful perspectives from academic and community oncologists on published, peer-reviewed content.

GALAXY Study: ctDNA-Based MRD Monitoring in Resected CRC

EP: 1.Colorectal Cancer: Rising Prevalence and the Promise of ctDNA

EP: 2.ctDNA in CRC Management: Evolving Approaches for Personalized Care

EP: 3.MRD Detection in CRC: Guiding Postsurgical Treatment Decisions and Monitoring

EP: 4.MRD Testing in CRC: Optimizing Chemo-Sparing Strategies and Residual Disease Control

EP: 5.DYNAMIC: ctDNA-Guided Therapy on Adjuvant Chemotherapy Decisions in Stage II Colon Cancer

EP: 6.ctDNA Insights From INTERCEPT, BESPOKE, COSMOS-CRC-01, and GALAXY Studies

EP: 7.GALAXY Study: ctDNA-Based MRD Monitoring in Resected CRC

EP: 8.GALAXY Study Results: ctDNA Status Predicts Outcomes and Treatment Benefit in CRC